TBIO stock forecast
Our latest prediction for Translate Bio, Inc.'s stock price was made on the June 30, 2020 when the stock price was at 17.92$.
In the short term (2weeks), TBIO's stock price should underperform the market by -2.96%. During that period the price should oscillate between -12.56% and +11.44%.
In the medium term (3months), TBIO's stock price should underperform the market by -7.99%. During that period the price should oscillate between -40.74% and +26.45%.Get email alerts
Create a solid portfolio with TBIO
About Translate Bio, Inc.
Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.
At the moment the company generates 11M USD in revenues.
On its last earning announcement, the company reported a loss of -1.70$ per share.
The book value per share is 2.27$
Three months stock forecastJune 30, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|